The team decided to stop use of an inhibitor drug for advanced liver cancer in light of Liu's rapidly deteriorating liver functions, according to a statement today on the website of the First Hospital of China Medical University.
It said a traditional Chinese medicine anti-tumor treatment was also suspended while low-molecular heparin had been added to treat venous thrombosis developing in Liu's left leg.
Zeng Jinyan, a close family friend in contact with Liu's brother-in-law Liu Hui, confirmed today that Liu's situation was not optimistic.
Citing Liu Hui, Zeng said the inhibitor drug, Sorafenib, has failed to work on Liu Xiaobo.
"He is yet to see any improvement after two to three weeks, but its side effects are causing his liver functions to badly deteriorate with severe accumulation of abdominal fluid," Zeng wrote in a statement posted online. "So the drug must be suspended, and the focus has shifted to preserve his liver and to give his body a chance to breathe."
He was awarded the Nobel Peace Prize in 2010, the year after he was convicted and jailed by a Chinese court.
In the years since, China has ignored international calls to free Liu while isolating him to the degree that he's been unable to convey any message to the outside world.
His wife, Liu Xia, has been under strict house arrest in Beijing despite never being accused of any crime. Even after he was transferred to the hospital in the northeastern city of Shenyang under a medical parole, Liu, his wife and family members were largely prevented from communicating with the outside.
Although the Chinese government has so far showed no sign that it would free Liu or allow him to travel overseas, it has acceded to family requests to allow liver cancer experts from Germany, the US and elsewhere to join the Chinese medical team treating Liu.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
